SHERWIN WILLIAMS CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SHERWIN WILLIAMS CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $4.11B | Feb 21, 2020 |
| FY2019 | Sep 30, 2019 | $4.87B | Feb 21, 2020 |
| FY2019 | Jun 30, 2019 | $4.88B | Feb 21, 2020 |
| FY2019 | Mar 31, 2019 | $4.04B | Feb 21, 2020 |
| FY2019 | Dec 31, 2018 | $4.06B | Feb 21, 2020 |
| FY2019 | Sep 30, 2018 | $4.73B | Feb 21, 2020 |
| FY2019 | Jun 30, 2018 | $4.77B | Feb 21, 2020 |
| FY2019 | Mar 31, 2018 | $3.97B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $3.98B | Feb 22, 2019 |
| FY2018 | Sep 30, 2017 | $4.51B | Feb 22, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.57B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $23.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $23.05B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $22.15B | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | $4.76B | Feb 17, 2022 |
| FY2021 | Sep 30, 2021 | $5.15B | Feb 17, 2022 |
| FY2021 | Jun 30, 2021 | $5.38B | Feb 17, 2022 |
| FY2021 | Mar 31, 2021 | $4.66B | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | $4.49B | Feb 17, 2022 |
| FY2021 | Sep 30, 2020 | $5.12B | Feb 17, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.98B | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $4.51B | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $3.74B | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $2.76B | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $2.78B | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $3.28B | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $3.22B | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $2.57B | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $2.60B | Feb 22, 2017 |
| FY2016 | Sep 30, 2015 | $3.15B | Feb 22, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.52B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $11.20B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $10.76B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $9.33B | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | $1.88B | Feb 17, 2022 |
| FY2021 | Sep 30, 2021 | $2.14B | Feb 17, 2022 |
| FY2021 | Jun 30, 2021 | $2.41B | Feb 17, 2022 |
| FY2021 | Mar 31, 2021 | $2.11B | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | $2.13B | Feb 17, 2022 |
| FY2021 | Sep 30, 2020 | $2.46B | Feb 17, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.57B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.68B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.39B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.02B | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | $304.00M | Feb 17, 2022 |
| FY2021 | Sep 30, 2021 | $502.20M | Feb 17, 2022 |
| FY2021 | Jun 30, 2021 | $648.60M | Feb 17, 2022 |
| FY2021 | Mar 31, 2021 | $409.60M | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | $407.00M | Feb 17, 2022 |
| FY2021 | Sep 30, 2020 | $705.80M | Feb 17, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.16B | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | $3.40B | Feb 20, 2024 |
| FY2023 | Dec 31, 2021 | $3.08B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $3.37B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $2.81B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $2.61B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $2.24B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $2.16B | Feb 22, 2019 |
| FY2017 | Dec 31, 2015 | $1.96B | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $1.70B | Feb 22, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $51.92M | Feb 22, 2019 |
| FY2017 | Dec 31, 2017 | $58.47M | Feb 23, 2018 |
| FY2016 | Dec 31, 2016 | $58.04M | Feb 22, 2017 |
| FY2015 | Dec 31, 2015 | $57.67M | Feb 24, 2016 |
| FY2014 | Dec 31, 2014 | $50.02M | Feb 25, 2015 |
| FY2013 | Dec 31, 2013 | $47.04M | Feb 27, 2014 |
| FY2012 | Dec 31, 2012 | $44.65M | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $41.72M | Feb 28, 2013 |
| FY2012 | Dec 31, 2010 | $39.88M | Feb 28, 2013 |
| FY2010 | Dec 31, 2009 | $40.43M | Feb 23, 2011 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $7.42B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $7.07B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $6.33B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $5.88B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $5.48B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $5.27B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $5.03B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $4.80B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $4.14B | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.45B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.15B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.52B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.92B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.24B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $3.41B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $2.32B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $1.94B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $1.88B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.31B | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $125.16M | Feb 23, 2011 |
| FY2009 | Dec 31, 2009 | $91.33M | Feb 24, 2010 |
| FY2009 | Dec 31, 2008 | $117.20M | Feb 24, 2010 |
| FY2009 | Dec 31, 2007 | $165.87M | Feb 24, 2010 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.90B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $23.63B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $22.95B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $22.59B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $20.67B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $20.40B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $20.50B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $19.13B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $19.90B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $6.75B | Feb 22, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.60B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.05B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.72B | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $3.10B | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $2.44B | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $3.61B | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $4.12B | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $3.73B | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $3.65B | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $1.88B | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.04B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $7.58B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $7.63B | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $7.58B | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $7.13B | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $7.05B | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $7.00B | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $6.96B | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $6.81B | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $1.13B | Feb 21, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $7.25B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $5.29B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.52B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.12B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $844.30M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $7.37B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $6.25B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $5.46B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $4.05B | Feb 22, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $207.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $210.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $276.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $198.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $165.70M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $226.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $161.80M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $155.50M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $204.20M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $889.79M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.67B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $9.23B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $9.48B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $9.59B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $8.85B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $8.29B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $8.48B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $9.02B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $9.89B | Feb 21, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 10 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | 1 | Feb 17, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Feb 17, 2022 |
| FY2021 | Jun 30, 2021 | 2 | Feb 17, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | 1 | Feb 17, 2022 |
| FY2021 | Sep 30, 2020 | 2 | Feb 17, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 10 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | 1 | Feb 17, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Feb 17, 2022 |
| FY2021 | Jun 30, 2021 | 2 | Feb 17, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | 1 | Feb 17, 2022 |
| FY2021 | Sep 30, 2020 | 2 | Feb 17, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 247.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 251.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 254.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 258.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 261.10M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | 268.70M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 276.40M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | 93.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 93.88M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 93.01M | Feb 22, 2019 |